Search PubMed⌕ Search

Biomedical subjects

B A Morris

Publications and source records attributed to B A Morris.

86 records · Page 5Linked to original sources
PubMed1971

Familial hyperparathyroidism.

Twenty-eight members of a family over three generations were studied; six of them had hyperparathyroidism. Four of the six were siblings and one of these had suffered from recurrent hyperparathyroidism. No member of the family showed any other significant endocrine disturbance or active peptic ulceration.Attention is drawn to the prominent lack of symptoms despite dangerous levels of hypercalcaemia and advanced disease with the consequent need for estimation of serum calcium levels in all close relatives. Multiple gland involvement is common in familial hyperparathyroidism and is often coupled with a tendency to recurrence, necessitating long-term follow-up. Histological appearances vary considerably, and the risk of recurrence is not limited to cases showing primary chief cell hyperplasia, with the implication that resection of three parathyroid glands and part of the remaining gland may be the treatment of choice in all cases of familial hyperparathyroidism when multiple gland involvement is found.

Adenoma↗
PubMed1970

Clinical and metabolic study in diabetic patients treated with glibenclamide.

A clinical and metabolic study of 32 patients treated with glibenclamide for a period of about one year confirmed that the drug is a potent stimulator of insulin release in maturity onset diabetes, and glibenclamide continued to have this action after a period of eight months. The drug is effective in doses as low as 2.5 mg., and the maximum effective dose is about 15 mg. No significant side-effects were found during the period of the study, in particular there was no alcohol flushing. The metabolic investigations have shown that the drug has some actions which are as yet unexplained.

Adult↗
PubMedDate not supplied

A propranolol radioimmunoassay and its use in the study of its pharmacokinetics following low doses.

A radioimmunoassay has been developed for propranolol with a sensitivity of 2.37 nmol l-1 in unextracted plasma using a 50 microliter sample. Plasma concentration measurements were made on samples from volunteers for up to 8 h after they had been given 5, 10, or 40 mg of propranolol by mouth. Analysis of the results showed that mean elimination half-lives and total body clearances were similar following each of the doses and that the area under the curve was proportional to the dose. Steady-state propranolol concentrations in 17 patients on regular propranolol treatment were linearly related to the dose ver the range 20-640 mg d-1; the regression line extrapolated to the origin. These data indicate non-saturable kinetics for the hepatic metabolism of propranolol within the dose ranges investigated and lead us to believe that there is no 'oral-threshold' dose for propranolol. The radioimmunoassay may be useful in clinical practice for monitoring plasma propranolol concentrations and for detecting patient compliance.

Adult↗
PubMedDate not supplied

The use of low molecular weight heparins in the prevention of venous thromboembolic disease.

Deep vein thrombosis (DVT) and pulmonary embolism (PE) are leading causes of morbidity and mortality in the United States. Estimates range between 300,000 and 600,000 hospitalizations a year, with approximately 50,000 deaths related to PE. The incidence of the complication of DVT following total joint replacement is reported to occur in 50% to 75% of all unprotected patients. The increasing number of adults who undergo a total joint replacement dictates that orthopaedic nurses become a vital part of the development team that (1) identifies contributing factors to each patient's risk profile, (2) decreases this risk, and (3) refines the patient's transition through the acute hospitalization into the home or rehabilitation environment. The results of recent studies with a new class of heparins, the low molecular weight heparins, suggest their superiority and demonstrate improvement in decreasing the risk of developing DVT and subsequent PE in the total hip and knee patient population.

Adult↗
PubMedDate not supplied

Promotion of bicycle helmet use among schoolchildren: a randomized clinical trial.

Although bicycle helmets have been shown to reduce the rates of head injuries and brain injuries from bicycle mishaps, use of helmets is very uncommon. We compared a comprehensive awareness program to increase bicycle helmet use among schoolchildren to the impact of that same awareness program plus a bicycle helmet subsidy. Results showed no impact of the educational program (no children observed riding to school wore helmets before or after the program). The proportion of helmet wearers at the school that obtained the subsidy increased from 0% to 22% (p = 0.036). An educational program in conjunction with a subsidy may have a significant impact on bicycle helmet use.

Adolescent↗
PubMedDate not supplied

Nursing care for the prevention of deep vein thrombosis.

1. Deep vein thrombosis (DVT) and pulmonary embolism (PE) are major health problems that often result in significant postsurgical morbidity and mortality. 2. To prevent DVT, patient care includes graduated compression stockings or the use of a pneumatic compression device, and administration of the correct dose of anticoagulation agent (heparin or LMWH). 3. Taken together, the various drug therapies and physical interventions can clearly prevent DVT. Careful evaluation of the patient's risk factors, along with a monitored postoperative therapy can minimize the morbidity and mortality of this "unseen" condition.

Anticoagulants↗